Identification of pathways modulating vemurafenib resistance in melanoma cells via a genome-wide CRISPR/Cas9 screen
Open accessPublished version of a preprint
The DOI matches its Crossref record; 75 of the 76 references it cites were found in a registry or an index.
Abstract
Vemurafenib is a BRAF kinase inhibitor (BRAFi) that is used to treat melanoma patients harboring the constitutively active BRAF-V600E mutation. However, after a few months of treatment patients often develop resistance to vemurafenib leading to disease progression. Sequence analysis of drug-resistant tumor cells and functional genomic screens has identified several genes that regulate vemurafenib resistance. Reactivation of mitogen-activated protein kinase (MAPK) pathway is a recurrent feature of cells that develop resistance to vemurafenib. We performed a genome-scale CRISPR-based knockout screen to identify modulators of vemurafenib resistance in melanoma cells with a highly improved CRISPR sgRNA library called Brunello. We identified 33 genes that regulate resistance to vemurafenib out of which 14 genes have not been reported before. Gene ontology enrichment analysis showed that the hit genes regulate histone modification, transcription and cell cycle. We discuss how inactivation of hit genes might confer resistance to vemurafenib and provide a framework for follow-up investigations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Many of the identified mediator complex components were concordantly associated with resistance to other targeted cancer therapies,44,45 but were also controversially identified as essential genes in CML cells.46”
From Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia (2024) · cites this paper as [45]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nature Protocols · doi:10.1038/nprot.2008.211 · Cited by 35,890 · cited 5×
“Gene Ontology (GO) term enrichment analysis was performed using DAVID [19][20].”
MethodInfluentialSzklarczyk, D., Gable, A. L., Lyon, D., Junge, A., Wyder, S., Huerta-Cepas, J., Simonovic, M., Doncheva, N. T., Morris, J. H., Bork, P., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1131 · Cited by 17,749
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn923 · Cited by 14,108 · cited 2×
“Gene 168 Ontology (GO) term enrichment analysis was performed using DAVID [19][20].”
MethodREVIGO summarizes and visualizes long lists of gene ontology terms
Supek, F., Bošnjak, M., Škunca, N., & Šmuc, T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021800 · Cited by 6,264 · cited 3×
“We removed the redundant GO terms using the online tool REVIGO [21].”
MethodInfluentialImproved vectors and genome-wide libraries for CRISPR screening
Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239 · cited 1×
“An improved GeCKOv2 library with minimal off-target effects and covering 19,050 human genes with 6 sgRNAs per gene (Sanjana et al. 2014) was used for a positive selection screen with vemurafenib.”
MethodGenome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234 · cited 4×
“Seminal work on the genome-wide 77 CRISPR KnockOut (GeCKO) screen [11] for regulators for vemurafenib resistance was 78 performed with two half sgRNA GeCKOv1 libraries, covering 18,000 human genes with a total 79 of 6 target sgRNAs per gene.”
BackgroundInfluentialOptimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
Doench, J. G., Fusi, N., Sullender, M., Hegde, M., Vaimberg, E. W., Donovan, K. F., Smith, I., Tothova, Z., Wilen, C., Orchard, R., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3437 · Cited by 4,637 · cited 4×
“(2017) used GeCKOv2 80 libraries to screen for the vemurafenib resistant A375 cells [12], [13].”
BackgroundMethodInfluentialLi, W., Xu, H., Xiao, T., Cong, L., Love, M. I., Zhang, F., Irizarry, R. A., Liu, J. S., Brown, M., & Liu, X. S. (2014) · Genome Biology · doi:10.1186/s13059-014-0554-4 · Cited by 2,684 · cited 3×
“Model-based 162 Analysis of Genome-wide CRISPR/Cas9 Knockout (MAGeCK) was chosen for our analysis 163 which scores whether each gene is enriched or depleted and generates a gene ranking list [16].”
BackgroundMethodGenomic instability — an evolving hallmark of cancer
Negrini, S., Gorgoulis, V. G., & Halazonetis, T. D. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2858 · Cited by 2,397 · cited 1×
“Therefore, loss of HIRA and SMARCA4 is expected to cause genomic 313 instability, a hallmark of tumour cells [34].”
BackgroundLimb proportions show developmental plasticity in response to embryo movement
Pollard, A. S., Charlton, B. G., Hutchinson, J. R., Gustafsson, T., McGonnell, I. M., Timmons, J. A., & Pitsillides, A. A. (2017) · Scientific Reports · doi:10.1038/srep41926 · Cited by 2,364
Cui, P., Zhang, S., Ding, F., Ali, S., & Xiong, L. (2014) · Genome Biology · doi:10.1186/gb-2014-15-1-r1 · Cited by 2,294
No evidence that carotenoid pigments boost either immune or antioxidant defenses in a songbird
Koch, R. E., Kavazis, A. N., Hasselquist, D., Hood, W. R., Zhang, Y., Toomey, M. B., & Hill, G. E. (2018) · Nature Communications · doi:10.1038/s41467-018-02974-x · Cited by 1,924
Non-Smad pathways in TGF-β signaling
Zhang, Y. E. (2009) · Cell Research · doi:10.1038/cr.2008.328 · Cited by 1,749
The Genetic Evolution of Melanoma from Precursor Lesions
Shain, A. H., Yeh, I., Kovalyshyn, I., Sriharan, A., Talevich, E., Gagnon, A., Dummer, R., North, J., Pincus, L., Ruben, B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502583 · Cited by 1,065 · cited 1×
“Mutations in SWI/SNF chromatin remodeling genes have been associated with invasive melanomas (Shain et al. 2015).”
BackgroundOptimized libraries for CRISPR-Cas9 genetic screens with multiple modalities
Sanson, K. R., Hanna, R. E., Hegde, M., Donovan, K. F., Strand, C., Sullender, M. E., Vaimberg, E. W., Goodale, A., Root, D. E., Piccioni, F., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07901-8 · Cited by 1,043 · cited 3×
“Studies of epigenomic alterations revealed a loss of histone 295 acetylation and histone H3 Lys 4 methylation (H3K4me2/3) on regulatory regions proximal to 296 specific cancer-regulatory genes involved in important signalling pathways driving melanoma 297 [14].”
BackgroundMethodInfluentialHarmancı, A. S., Youngblood, M. W., Clark, V. E., Coşkun, S., Henegariu, O., Duran, D., Erson-Omay, E. Z., Kaulen, L. D., Lee, T. I., Abraham, B. J., et al. (2018) · Nature Communications · doi:10.1038/ncomms16215 · Cited by 905
Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF
Haq, R., Shoag, J., Andreu-Perez, P., Yokoyama, S., Edelman, H., Rowe, G. C., Frederick, D. T., Hurley, A. D., Nellore, A., Kung, A. L., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.003 · Cited by 818 · cited 1×
“BRAF mutant cells have increased rates of glycolysis and reduced oxidative phosphorylation in comparison to wild type cells (Haq et al. 2013).”
BackgroundThe role of BRAF V600 mutation in melanoma
Ascierto, P. A., Kirkwood, J. M., Grob, J.-J., Simeone, E., Grimaldi, A. M., Maio, M., Palmieri, G., Testori, A., Marincola, F. M., & Mozzillo, N. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-85 · Cited by 801 · cited 2×
“Although there is short-term tumor regression and enhancement of patient survival, resistance to vemurafenib frequently develops (Ascierto et al. 2012).”
BackgroundEndonucleolytic cleavage of eukaryotic mRNAs with stalls in translation elongation
Doma, M. K., & Parker, R. (2006) · Nature · doi:10.1038/nature04530 · Cited by 760 · cited 1×
“PELO 344 is involved in the no-go decay (NGD) surveillance mechanism which leads to mRNA 345 degradation in stalled ribosomal elongation complexes (ECs) [44].”
BackgroundModelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
Das Thakur, M., Salangsang, F., Landman, A. S., Sellers, W. R., Pryer, N. K., Levesque, M. P., Dummer, R., McMahon, M., & Stuart, D. D. (2013) · Nature · doi:10.1038/nature11814 · Cited by 730
Morris, E. J., Jha, S., Restaino, C. R., Dayananth, P., Zhu, H., Cooper, A., Carr, D., Deng, Y., Jin, W., Black, S., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0070 · Cited by 676 · cited 1×
“On the other hand, excessive 58 MAPK output causes toxicity [4], [5].”
BackgroundThe immune score as a new possible approach for the classification of cancer
Galon, J., Pagès, F., Marincola, F. M., Thurin, M., Trinchieri, G., Fox, B. A., Gajewski, T. F., & Ascierto, P. A. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-1 · Cited by 628
Role of Merlin/NF2 inactivation in tumor biology
Petrilli, A. M., & Fernández-Valle, C. (2016) · Oncogene · doi:10.1038/onc.2015.125 · Cited by 458 · cited 3×
“Loss of merlin activates other growth 279 promoting pathways such as Hippo and mTOR [25] explaining the incidence of NF2 mutations 280 in several forms of cancers.”
BackgroundInfluentialBrownstein, C. A., Beggs, A. H., Homer, N., Merriman, B., Yu, T. W., Flannery, K. C., DeChene, E. T., Towne, M. C., Savage, S. K., Price, E. N., et al. (2014) · Genome Biology · doi:10.1186/gb-2014-15-3-r53 · Cited by 432
MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling
Huang, S., Hölzel, M., Knijnenburg, T., Schlicker, A., Roepman, P., McDermott, U., Garnett, M., Grernrum, W., Sun, C., Prahallad, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.10.035 · Cited by 430 · cited 1×
“Mutations in MED12 confer resistance to a number of drugs used against colon cancer, melanoma and liver cancer (Huang et al. 2012).”
BackgroundSystematic comparison of CRISPR/Cas9 and RNAi screens for essential genes
Morgens, D. W., Deans, R. M., Li, A., & Bassik, M. C. (2016) · Nature Biotechnology · doi:10.1038/nbt.3567 · Cited by 401
Measuring error rates in genomic perturbation screens: gold standards for human functional genomics
Hart, T., Brown, K. R., Sircoulomb, F., Rottapel, R., & Moffat, J. (2014) · Molecular Systems Biology · doi:10.15252/msb.20145216 · Cited by 398 · cited 1×
“GeCKOv2, Avana and Brunello libraries were compared in their abilities to target the gold-standard gene sets of 1580 essential and 927 nonessential genes (Hart et al. 2014).”
Martinez, E., Palhan, V. B., Tjernberg, A., Lymar, E. S., Gamper, A. M., Kundu, T. K., Chait, B. T., & Roeder, R. G. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.20.6782-6795.2001 · Cited by 382 · cited 1×
“STAGA is a chromatin-acetylating transcription coactivator and regulates numerous cellular processes like transcription, splicing and DNA repair through coordination of multiple histone post-translational modifications (Martinez et al. 2001; Baker and Grant 2007).”
BackgroundTranslational Control in Cancer Etiology
Ruggero, D. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012336 · Cited by 367 · cited 1×
“Misregulation of protein translation is a key mechanism that drives cellular transformation and tumor growth (Ruggero 2013).”
BackgroundA Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition
Whittaker, S. R., Theurillat, J.-P., Van Allen, E., Wagle, N., Hsiao, J., Cowley, G. S., Schadendorf, D., Root, D. E., & Garraway, L. A. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0470 · Cited by 359 · cited 1×
“Whittaker et al. (2013) used genome-scale RNA interference screen with a library size of 90,000 shRNAs targeting approximately 16,600 genes expressed in A375 cells [10].”
MethodThe human CST complex is a terminator of telomerase activity
Chen, L.-Y., Redon, S., & Lingner, J. (2012) · Nature · doi:10.1038/nature11269 · Cited by 348 · cited 2×
“Another novel hit Ctc1 is a component of the CST (Ctc1, Stn1 and Ten1) complex, which 368 functions as a terminator of telomerase activity [52].”
BackgroundPisareva, V. P., Skabkin, M. A., Hellen, C. U. T., Pestova, T. V., & Pisarev, A. V. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.93 · Cited by 296 · cited 1×
“PELO is an evolutionarily conserved gene [42] required for ribosomal disassembly [43].”
BackgroundOgilvie, S. P., Large, M. J., Fratta, G., Meloni, M., Canton-Vitoria, R., Tagmatarchis, N., Massuyeau, F., Ewels, C. P., King, A. A. K., & Dalton, A. B. (2017) · Scientific Reports · doi:10.1038/s41598-017-17123-5 · Cited by 270
Obesity and Breast Cancer: Role of Leptin
Sánchez-Jiménez, F., Pérez-Pérez, A., de la Cruz-Merino, L., & Sánchez-Margalet, V. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00596 · Cited by 268
Melanoma cells influence the differentiation pattern of human epidermal keratinocytes
Kodet, O., Lacina, L., Krejčí, E., Dvořánková, B., Grim, M., Štork, J., Kodetová, D., Vlček, Č., Šáchová, J., Kolář, M., et al. (2015) · Molecular Cancer · doi:10.1186/1476-4598-14-1 · Cited by 267
Kissil, J. L., Wilker, E. W., Johnson, K. C., Eckman, M. S., Yaffe, M. B., & Jacks, T. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00382-4 · Cited by 257 · cited 2×
“276 Merlin inhibits Rac by preventing its localization to the plasma membrane [26] and by 277 inhibiting the p21-activated kinase PAK1 [27].”
BackgroundThe NF1 gene in tumor syndromes and melanoma
Kiuru, M., & Busam, K. J. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2016.142 · Cited by 217 · cited 1×
“NF1 negatively regulates RAS by stimulating its GTPase activity [22].”
BackgroundThe SAGA continues: expanding the cellular role of a transcriptional co-activator complex
Baker, S. P., & Grant, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210603 · Cited by 214 · cited 1×
“transcription, splicing and DNA repair through coordination of multiple histone post305 translational modifications [29], [30].”
BackgroundRac signaling in breast cancer: A tale of GEFs and GAPs
Wertheimer, E., Gutierrez-Uzquiza, A., Rosemblit, C., Lopez-Haber, C., Sosa, M. S., & Kazanietz, M. G. (2012) · Cellular Signalling · doi:10.1016/j.cellsig.2011.08.011 · Cited by 203
Yadav, V., Zhang, X., Liu, J., Estrem, S., Li, S., Gong, X.-Q., Buchanan, S., Henry, J. R., Starling, J. J., & Peng, S.-B. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.377218 · Cited by 200
Okada, T., Lopez-Lago, M., & Giancotti, F. G. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200503165 · Cited by 195 · cited 1×
“276 Merlin inhibits Rac by preventing its localization to the plasma membrane [26] and by 277 inhibiting the p21-activated kinase PAK1 [27].”
BackgroundLuebker, S. A., & Koepsell, S. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00268 · Cited by 194 · cited 2×
“Reactivation of MAPK pathway and/or activation of PI3K/AKT pathways confer 65 resistance to BRAFi in melanoma cells [9].”
BackgroundCorazao-Rozas, P., Guerreschi, P., Jendoubi, M., André, F., Jonneaux, A., Scalbert, C., Garçon, G., Malet-Martino, M., Balayssac, S., Rocchi, S., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1420 · Cited by 178 · cited 1×
“Treatment of BRAF mutant cells with 352 vemurafenib reduces glycolytic flux and increases mitochondrial oxidative phosphorylation 353 resulting in severe oxidative stress [49].”
BackgroundGui, T., Sun, Y., Shimokado, A., & Muragaki, Y. (2012) · Journal of Signal Transduction · doi:10.1155/2012/289243 · Cited by 146 · cited 1×
“Binding of TGF-b activates TGFbR which activates Ras by promoting the formation of ShcA/ Grb2/Sos complex (Zhang, 2009; Chapnick et al. 2011; Gui et al. 2012) (Supplementary Figure S3).”
BackgroundPartners in crime: the TGFβ and MAPK pathways in cancer progression
Chapnick, D. A., Warner, L., Bernet, J. D., Rao, T., & Liu, X. (2011) · Cell & Bioscience · doi:10.1186/2045-3701-1-42 · Cited by 134 · cited 1×
“Binding of TGF-b activates TGFbR which activates Ras by promoting the formation of ShcA/ Grb2/Sos complex (Zhang, 2009; Chapnick et al. 2011; Gui et al. 2012) (Supplementary Figure S3).”
BackgroundIn Vivo Consequences of Disrupting SH3-Mediated Interactions of the Inducible T-Cell Kinase
Levytskyy, R. M., Hirve, N., Guimond, D. M., Min, L., Andreotti, A. H., & Tsoukas, C. D. (2012) · Journal of Signal Transduction · doi:10.1155/2012/694386 · Cited by 117
RAC1 Takes the Lead in Solid Tumors
De, P., Aske, J. C., & Dey, N. (2019) · Cells · doi:10.3390/cells8050382 · Cited by 106 · cited 1×
“RAC1-GTP activates PAK1 (Supplementary Figure S3), leading to the downstream activation of MEK and bypassing the upstream BRAF inhibition (De et al. 2019).”
BackgroundCorre, S., Tardif, N., Mouchet, N., Leclair, H. M., Boussemart, L., Gautron, A., Bachelot, L., Perrot, A., Soshilov, A., Rogiers, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06951-2 · Cited by 98 · cited 2×
“Vemurafenib was shown to bind to a non-canonical 362 substrate binding site of AHR and inhibit the canonical AHR signalling pathway [50].”
BackgroundReshaping Chromatin after DNA Damage: The Choreography of Histone Proteins
Polo, S. E. (2014) · Journal of Molecular Biology · doi:10.1016/j.jmb.2014.05.025 · Cited by 89
FOXD3 Is a Mutant B-RAF–Regulated Inhibitor of G1-S Progression in Melanoma Cells
Abel, E. V., & Aplin, A. E. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3139 · Cited by 88 · cited 4×
“As a potent antagonist of melanoma 321 proliferation [36], FOXD3 prevents melanoma cell migration and invasion in a Rho-associated 322 protein kinase dependent manner [37].”
BackgroundInfluentialGenome-wide CRISPR-Cas9 screening in mammalian cells
Yu, J., & Yusa, K. (2019) · Methods · doi:10.1016/j.ymeth.2019.04.015 · Cited by 72
DNA repair goes hip-hop: SMARCA and CHD chromatin remodellers join the break dance
Rother, M. B., & van Attikum, H. (2017) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2016.0285 · Cited by 70 · cited 1×
“310 SMARCA4 promotes chromatin accessibility around double-strand breaks (DSBs) [32] and 311 HIRA is recruited to DSBs, facilitating restoration of chromatin structure by depositing 312 histones [33].”
BackgroundMechanistic insight into activation of MAPK signaling by pro-angiogenic factors
Song, M., & Finley, S. D. (2018) · BMC Systems Biology · doi:10.1186/s12918-018-0668-5 · Cited by 69
Identifying the Ubiquitin Ligase Complex That Regulates the NF1 Tumor Suppressor and Ras
Hollstein, P. E., & Cichowski, K. M. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0146 · Cited by 67 · cited 8×
“NF1 negatively regulates RAS by stimulating its GTPase activity [22].”
BackgroundInfluentialTargeting Oncogenic BRAF in Human Cancer
Pratilas, C. A., Xing, F., & Solit, D. B. (2010) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2011_162 · Cited by 61 · cited 1×
“BRAF, the target of vemurafenib, is the RAF component of the MAPK signaling pathway that is frequently hyperactivated in cancer cells (Pratilas et al. 2012), MAPK pathway consists of 1G protein RAS, and 3 kinases RAF, MEK, and ERK.”
BackgroundVanneste, M., Feddersen, C. R., Varzavand, A., Zhu, E. Y., Foley, T. M., Zhao, L. Q., Holt, K. H., Milhem, M. M., Piper, R. C., Stipp, C. S., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00442 · Cited by 60
An evolutionarily conserved ribosome-rescue pathway maintains epidermal homeostasis
Liakath‐Ali, K., Mills, E. W., Sequeira, I., Lichtenberger, B. M., Pisco, A. O., Sipilä, K. H., Mishra, A., Yoshikawa, H., Wu, C. C., Ly, T., et al. (2018) · Nature · doi:10.1038/s41586-018-0032-3 · Cited by 60 · cited 1×
“Furthermore, conditional 348 deletion of PELO in mouse epidermal stem cells resulted in their hyperproliferation [47].”
Multiple cancer pathways regulate telomere protection
Bejarano, L., Bosso, G., Louzame, J., Serrano, R., Gómez‐Casero, E., Martinez-Torrecuadrada, J. L., Martínez, S., Blanco‐Aparicio, C., Pastor, J., & Blasco, M. A. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201910292 · Cited by 58
le Sage, C., Lawo, S., Panicker, P., Scales, T. M. E., Rahman, S. A., Little, A. S., McCarthy, N. J., Moore, J. D., & Cross, B. C. S. (2017) · Scientific Reports · doi:10.1038/s41598-017-18172-6 · Cited by 57 · cited 4×
“(2017) used GeCKOv2 80 libraries to screen for the vemurafenib resistant A375 cells [12], [13].”
BackgroundMethodInfluentialCRISPRAnalyzeR: Interactive analysis, annotation and documentation of pooled CRISPR screensPreprint
Winter, J., Schwering, M., Pelz, O., Rauscher, B., Zhan, T., Heigwer, F., & Boutros, M. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/109967 · Cited by 56 · cited 1×
“org) [15] for analysis of 157 phenotypes against the reference Brunello library.”
ROCK 1 is a potential combinatorial drug target for BRAF mutant melanoma
Smit, M. A., Maddalo, G., Greig, K., Raaijmakers, L. M., Possik, P. A., van Breukelen, B., Cappadona, S., Heck, A. J., Altelaar, A. M., & Peeper, D. S. (2014) · Molecular Systems Biology · doi:10.15252/msb.20145450 · Cited by 54
Independent mechanisms recruit the cohesin loader protein NIPBL to sites of DNA damage
Bot, C., Pfeiffer, A., Giordano, F., Manjeera, D. E., Dantuma, N. P., & Ström, L. (2017) · Journal of Cell Science · doi:10.1242/jcs.197236 · Cited by 53 · cited 1×
“MAU2 interacts with NIPBL/SCC2 to form a heterodimeric complex that is required for 329 loading of cohesin complex onto chromatin [39], [40].”
BackgroundFOXD3 Regulates Migration Properties and Rnd3 Expression in Melanoma Cells
Katiyar, P., & Aplin, A. E. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0454 · Cited by 47 · cited 1×
“As a potent antagonist of melanoma 321 proliferation [36], FOXD3 prevents melanoma cell migration and invasion in a Rho-associated 322 protein kinase dependent manner [37].”
BackgroundIn vitro loading of human cohesin on DNA by the human Scc2-Scc4 loader complex
Bermudez, V. P., Farina, A., Higashi, T. L., Du, F., Tappin, I., Takahashi, T. S., & Hurwitz, J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206840109 · Cited by 46 · cited 1×
“MAU2 interacts with NIPBL/SCC2 to form a heterodimeric complex that is required for 329 loading of cohesin complex onto chromatin [39], [40].”
BackgroundDioxin receptor regulates aldehyde dehydrogenase to block melanoma tumorigenesis and metastasis
Contador-Troca, M., Alvarez, A. M., Merino, J. M., Morales‐Hernández, A., Rodríguez, M. I., Rey-Barroso, J., Barrasa, E., Cerezo-Guisado, M. I., Catalina‐Fernández, I., Sáenz‐Santamaría, J., et al. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0419-9 · Cited by 45 · cited 3×
“AHR 365 knockdown promoted melanoma in mouse [51].”
BackgroundInfluentialChu, T.-L., Zhao, H., Li, Y., Chen, A., Sun, X., & Ge, J. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.03.019 · Cited by 41 · cited 1×
“Mutant BRAF signaling results in FOXD3 downregulation (Abel and Aplin 2010), which was also linked to epithelial–mesenchymal transition (EMT)-like phenotype (Chu et al. 2014).”
BackgroundAPOPT1/COA8 assists COX assembly and is oppositely regulated by UPS and ROS
Signes, A., Cerutti, R., Dickson, A. S., Benincá, C., Hinchy, E. C., Ghezzi, D., Carrozzo, R., Bertini, E., Murphy, M. P., Nathan, J. A., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201809582 · Cited by 40
Zecena, H., Tveit, D. M., Wang, Z., Farhat, A. M., Panchal, P., Liu, J., Singh, S. J., Sanghera, A., Bainiwal, A., Teo, S. Y., et al. (2018) · BMC Systems Biology · doi:10.1186/s12918-018-0554-1 · Cited by 38 · cited 1×
“Exposure of melanoma cell lines to incremental concentrations of vemurafenib resulted in drug 53 resistance [3].”
BackgroundThe Role of eIF4E in Response and Acquired Resistance to Vemurafenib in Melanoma
Zhan, Y., Dahabieh, M. S., Rajakumar, A., Dobocan, M. C., M’Boutchou, M.-N., Gonçalves, C., Lucy, S. L., Pettersson, F., Topisirović, I., van Kempen, L. C. L. T., et al. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.11 · Cited by 29
Resistance to Vemurafenib Can Be Reversible After Treatment Interruption
Mackiewicz-Wysocka, M., Krokowicz, Ł., Kocur, J., & Mackiewicz, J. (2014) · Medicine · doi:10.1097/md.0000000000000157 · Cited by 21 · cited 1×
“Hence, the need to re-establish dynamic equilibrium 59 with interrupted scheduled dosing of vemurafenib was emphasized [6].”
BackgroundPELO negatively regulates HER receptor signalling and metastasis
Pedersen, K., Canals, F., Prat, A., Tabernero, J. M., & Arribas, J. (2013) · Oncogene · doi:10.1038/onc.2013.35 · Cited by 20 · cited 3×
“PELO knockdown has been reported to activate PI3K/AKT [45], [46] and BMP (Bone Morphogenetic Protein) signalling pathways [46], which resulted in epidermal hyperplasia in mice [46].”
BackgroundInfluentialPelota Regulates Epidermal Differentiation by Modulating BMP and PI3K/AKT Signaling Pathways
Elkenani, M., Nyamsuren, G., Raju, P., Liakath‐Ali, K., Hamdaoui, A., Kata, A., Dressel, R., Klonisch, T. C., Watt, F. M., Engel, W., et al. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.04.020 · Cited by 18
Mouse pelota gene (Pelo): cDNA cloning, genomic structure, and chromosomal localization
Shamsadin, R., Adham, I. M., & Engel, W. (2002) · Cytogenetic and Genome Research · doi:10.1159/000064059 · Cited by 13
Torres‐Collado, A. X., Nazarian, R., & Jazirehi, A. R. (2017) · Tumor Biology · doi:10.1177/1010428317721620 · Cited by 11
Optimizing gene set annotations combining GO structure and gene expression data
Wang, D., Li, J., Liu, R., & Wang, Y. (2018) · BMC Systems Biology · doi:10.1186/s12918-018-0659-6 · Cited by 3
Cited by
Chehelgerdi, M., Chehelgerdi, M., Khorramian-Ghahfarokhi, M., Shafieizadeh, M., Mahmoudi, E., Eskandari, F., Rashidi, M., Arshi, A., & Mokhtari-Farsani, A. (2024) · Molecular Cancer · doi:10.1186/s12943-023-01925-5 · Cited by 251
Gene editing and its applications in biomedicine
Li, G., Li, X., Zhuang, S., Wang, L., Zhu, Y., Chen, Y., Sun, W. C., Wu, Z., Zhou, Z. L., Chen, J., et al. (2022) · Science China Life Sciences · doi:10.1007/s11427-021-2057-0 · Cited by 77
“CRISPR/Cas9 knockout screens are widely used and exhibit high consistency between independent screens from different laboratories with similar experimental settings (Goh et al., 2021; Shalem et al., 2014).”
BackgroundA Comprehensive Review of Various Therapeutic Strategies for the Management of Skin Cancer
Dachani, S. R., Kaleem, M., Mujtaba, M. A., Mahajan, N. M., Ali, S. A., Almutairy, A. F., Mahmood, D., Anwer, M. K., Ali, M. D., & Kumar, S. (2024) · ACS Omega · doi:10.1021/acsomega.3c09780 · Cited by 47
Schneider, L., Wies, C., Krieghoff‐Henning, E., Bucher, T.-C., Utikal, J. S., Schadendorf, D., & Brinker, T. J. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.01.021 · Cited by 33
The AhR‐SRC axis as a therapeutic vulnerability in BRAFi‐resistant melanoma
Paris, A., Tardif, N., Baietti, F. M., Berra, C., Leclair, H. M., Leucci, E., Galibert, M., & Corre, S. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202215677 · Cited by 26
Metadata
- Authors
- Goh, C. J. H., Wong, J. H., El Farran, C., Tan, B. X., Coffill, C. R., Loh, Y.-H., Lane, D., & Arumugam, P.
- Affiliations
- Agency for Science, Technology and Research (SG)
- Epigenetics and Cell Fates Laboratory, A*STAR Institute of Molecular and Cell Biology, Singapore 138673, Singapore
- Corresponding author
- Arumugam, Prakash
- Venue
- G3 Genes|Genomes|Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-01-11
- Volume
- 11
- Issue
- 2
- ISSN
- 2160-1836 (ISSN-L)
- PMC
- PMC8022920
- OpenAlex
- W3129457230
- Cited by
- 20
- References
- 76
- Citations by year
- 2026: 7 · 2024: 6 · 2023: 3 · 2022: 3 · 2021: 1
- FWCI
- 1.02
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- G3 Genes Genomes Genetics (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Agency for Science, Technology and Research (A*STAR)
- Industry Alignment Fund—Pre-Positioning Programme (H18/01/a0/B14)
- A*STAR Innovations in Food and Chemical Safety
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Keywords
- vemurafenib resistance, melanoma, BRAF V600E mutation, BRAF inhibitors, MAPK pathway reactivation, histone modifications, transcriptional regulation, cell cycle genes, drug resistance genes
- MeSH terms
- Vemurafenib, Humans, Melanoma, Mutation, Drug Resistance, Neoplasm, Cell Line, Tumor, Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.